Exai Bio Secures $67.5 Million Series A Financing To Advance Next-Generation, Rna-Based Liquid Biopsy Platform For Early Cancer Detection
Exai Bio Secures $67.5 Million Series A Financing To Advance Next-Generation, Rna-Based Liquid Biopsy Platform For Early Cancer Detection
12/09/21, 11:30 AM
Location
san franciscoMoney raised
$67.5 million
Round Type
series a
Exai Bio, a next-generation liquid biopsy company, today announced it has raised a $67.5 million Series A financing to accelerate development of its non-invasive, RNA-based liquid biopsy platform for early cancer detection. The financing was led by leading life sciences and tech investors Section 32 and Casdin Capital, with participation from Two Sigma Ventures, who have been integral to advancing cancer diagnostics and artificial intelligence/machine learning technologies.
Company Info
Company
Exai Bio
Location
san francisco, california, united states
Additional Info
Exai Bio is a next-generation liquid biopsy company. Its mission is to enable a world where cancer can be detected early, diagnosed accurately, treated in a personalized and targeted way, and ultimately cured. The company’s proprietary RNA and artificial intelligence-based liquid biopsy platform delivers clinical insights into cancer biology to enable the earliest, most accurate diagnosis of cancer.